Pfizer going ‘all in’ on obesity drug development, CEO Bourla says
(Reuters) -U.S. drugmaker Pfizer (NYSE:PFE) is going “all in” to develop its experimental obesity drug and has been recruiting more
(Reuters) -U.S. drugmaker Pfizer (NYSE:PFE) is going “all in” to develop its experimental obesity drug and has been recruiting more
(Reuters) – Smartphone shipments for Apple (NASDAQ:AAPL) and Samsung (KS:005930) declined in the fourth quarter globally, as they grapple with intense competition
(Reuters) -Allstate has been sued by the state of Texas, which accused the insurer on Monday of illegally tracking drivers through their
By Tim Hepher DUBLIN (Reuters) – AerCap, the world’s largest aircraft leasing company, said on Monday that potential new trade tariffs floated by
By John Kruzel WASHINGTON (Reuters) – The U.S. Supreme Court declined on Monday to hear a bid by Sunoco and other oil companies
(Reuters) – The Los Angeles wildfires, which have reduced entire neighborhoods to smoldering ruins and left an apocalyptic landscape, could become the
MILAN (Reuters) – An Italian court is expected to decide this week on a request by Telecom Italia (BIT:TLIT)’s (TIM)
WASHINGTON (Reuters) – U.S. District Judge Aileen Cannon allowed the Justice Department to release its special counsel report on President-elect Donald Trump’s
Investing.com — The administration of U.S. President Joe Biden has determined that China employs unfair policies and practices to gain dominance in
UK-exposed assets witnessed a significant sell-off on Friday, triggered by a confluence of spillovers from the US bond market and apprehensions regarding